Aprepitant in antiemetic combinations to prevent chemotherapy‐induced nausea and vomiting

Aprepitant is an oral neurokinin‐1 receptor antagonist which acts centrally to block chemotherapy‐induced emesis. Its main pathway of elimination is by the cytochrome p450 isozyme CYP3A4, which is the basis for drug interactions with dexamethasone and oral contraceptives. Aprepitant is well tolerated, and phase II trials in high‐dose cisplatin‐induced emesis showed that it is most effective when 125 mg orally is added to a 5‐hydroxytryptamine‐3 receptor antagonist and dexamethasone for acute emesis and then an 80 mg oral dose continued with dexamethasone on days 2 and 3 to prevent delayed emesis. Two pivotal phase III trials enrolling a total of 1099 patients showed that the complete control of emesis improved by 20% in patients receiving aprepitant as compared with standard therapy, with the most impressive differences being in delayed emesis. Control was maintained over multiple cycles and occurred in both males and females and young and old adults.

[1]  F. Roila,et al.  The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  R. de Wit,et al.  Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  C. Lines,et al.  Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone , 2003, Clinical pharmacology and therapeutics.

[4]  K. Horgan,et al.  Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy‐induced nausea and vomiting , 2003, Cancer.

[5]  R. Gralla,et al.  Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy‐induced nausea and vomiting , 2003, Cancer.

[6]  R. Naylor,et al.  Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. , 2003, European journal of cancer.

[7]  S. Waldman,et al.  Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. , 2003, Clinical therapeutics.

[8]  Richard Hargreaves,et al.  Imaging substance P receptors (NK1) in the living human brain using positron emission tomography. , 2002, The Journal of clinical psychiatry.

[9]  M. Decramer,et al.  Prevention of cisplatin‐induced acute and delayed emesis by the selective neurokinin‐1 antagonists, L‐758,298 and MK‐869 , 2002, Cancer.

[10]  M. Decramer,et al.  Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. , 2001, European journal of cancer.

[11]  D. Campos,et al.  Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Tye,et al.  The novel NK1 receptor antagonist MK–0869 (L–754,030) and its water soluble phosphoryl prodrug, L–758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets , 2000, Neuropharmacology.

[13]  D. Osoba,et al.  Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Kris,et al.  Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. , 1999, The New England journal of medicine.

[15]  D. Osoba,et al.  Effect of postchemotherapy nausea and vomiting on health-related quality of life , 1997, Supportive Care in Cancer.

[16]  J. Verweij,et al.  Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. , 1997, British Journal of Cancer.

[17]  L. Cubeddu,et al.  Are more antiemetic trials with a placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatin , 1996, Cancer.

[18]  J. Seitz,et al.  A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  I. Olver,et al.  Antiemetic study methodology: recommendations for future studies. , 1996, Oncology.

[20]  Gavin Kilpatrick,et al.  The broad‐spectrum anti‐emetic activity of the novel non‐peptide tachykinin NK1 receptor antagonist GR203040 , 1995, British journal of pharmacology.

[21]  W. Meyer,et al.  Therapy for localized Ewing's sarcoma of bone. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  S. Groshen,et al.  Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Kris,et al.  Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  S B Kaye,et al.  On the receiving end--patient perception of the side-effects of cancer chemotherapy. , 1983, European journal of cancer & clinical oncology.

[25]  G. Morrow.  Prevalence and correlates of anticipatory nausea and vomiting in chemotherapy patients. , 1982, Journal of the National Cancer Institute.